<div id="readability-page-1"><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 6,967 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the sale, the chief executive officer directly owned 226,106 shares of the company's stock, valued at approximately $11,888,653.48. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><ul><li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li></ul><p>Samarth Kulkarni also recently made the following trade(s): </p><ul><li>On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total value of $1,552,500.00. </li><li>On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. </li></ul><h2>CRISPR Therapeutics Price Performance</h2><p>Shares of CRSP stock traded down $1.18 on Friday, hitting $53.46. 1,297,432 shares of the stock traded hands, compared to its average volume of 1,744,686. The company's fifty day moving average is $53.90 and its 200 day moving average is $57.27. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The company has a market capitalization of $5.13 billion, a PE ratio of -8.20 and a beta of 1.72. </p><ul><li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li></ul><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business's revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) EPS.  As a group, equities research analysts expect that  CRISPR Therapeutics AG will post -5.16 EPS for the current year. </p><h2>Institutional Trading of CRISPR Therapeutics</h2><p>A number of institutional investors have recently made changes to their positions in CRSP. ARK Investment Management LLC increased its stake in shares of  CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company's stock valued at $551,777,000 after acquiring an additional 735,084 shares during the period.  Orbis Allan Gray Ltd boosted its stake in  CRISPR Therapeutics by 19.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company's stock valued at $312,026,000 after purchasing an additional 968,060 shares in the last quarter.  Capital International Investors increased its position in shares of  CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company's stock valued at $309,016,000 after purchasing an additional 243,487 shares during the period.  State Street Corp raised its stake in shares of  CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company's stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter.  Finally, GSK plc acquired a new stake in shares of  CRISPR Therapeutics in the fourth quarter valued at $168,890,000. 69.20% of the stock is owned by institutional investors and hedge funds. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p>A number of brokerages have commented on CRSP. Chardan Capital lifted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a &#34;buy&#34; rating in a research note on Saturday, February 14th. Robert W. Baird reduced their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, November 11th. Morgan Stanley  restated an &#34;underweight&#34; rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a &#34;sector perform&#34; rating in a research note on Tuesday, November 11th. Finally, Evercore  reissued an &#34;outperform&#34; rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Ten equities research analysts have rated the stock with a Buy rating, six have issued  a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $64.24.</p><p><b>Read Our Latest Research Report on CRSP</b></p><h2>CRISPR Therapeutics Company Profile</h2> (Get Free Report)<p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.  </p><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li><li>Free: The Crypto Summit That Could Change Your Life</li><li>From Quiet Compounder to 2026 Breakout? BSEM</li><li>Silver $309?</li><li>Gilder: Don’t Buy AI Stocks, Do This Instead</li><li>America’s 1776 happening again</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

CRSP

IBBQ

<p>CRISPR Therapeutics CEO Samarth Kulkarni sold 6,967 shares at $52.58 each, totaling $366,324.86, reducing his ownership by 2.99%. Post-sale, he holds 226,106 shares valued at approximately $11.89 million. This transaction was disclosed to the SEC. The company's stock recently traded at $53.46, with a market cap of $5.13 billion. CRISPR reported a quarterly EPS of ($1.37), missing estimates, and a revenue drop of 97.8% year-over-year. Institutional investors hold 69.20% of the stock, with recent changes in positions by several firms.</p>

Market Beat

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock